The GLP-1 receptor agonist liraglutide attenuates atherosclerotic lesion development and enhances plaque stability in an ApoE-/- mouse model

被引：0
|
作者：
Dear, A. E. [1 ]
Gaspari, T. [1 ]
Welungoda, I. [1 ]
Widdop, R. E. [1 ]
Simpson, R. W. [1 ]
机构：
[1] Monash Univ, Melbourne, Vic 3004, Australia
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
780
引用
收藏
页码：S321 / S321
页数：1
相关论文
共 50 条
  • [1] The GLP-1 Receptor Agonist Liraglutide Attenuates Atherosclerotic Lesion Development and Potentially Enhances Plaque Stability in an ApoE-/- Mouse Model
    Simpson, Richard W.
    Gaspari, Tracey
    Welungoda, Iresha
    Widdop, Robert E.
    Knudsen, Lotte B.
    Dear, Anthony E.
    DIABETES, 2012, 61 : A486 - A486
  • [2] The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model
    Gaspari, Tracey
    Welungoda, Iresha
    Widdop, Robert E.
    Simpson, Richard W.
    Dear, Anthony E.
    DIABETES & VASCULAR DISEASE RESEARCH, 2013, 10 (04): : 353 - 360
  • [3] A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
    Gaspari, Tracey
    Liu, HongBin
    Welungoda, Iresha
    Hu, Yunshan
    Widdop, Robert E.
    Knudsen, Lotte B.
    Simpson, Richard W.
    Dear, Anthony E.
    DIABETES & VASCULAR DISEASE RESEARCH, 2011, 8 (02): : 117 - 124
  • [4] A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model (vol 8, pg 117, 2011)
    Gaspari, Tracey
    Liu, HongBin
    Welungoda, Iresha
    Hu, Yunshan
    Widdop, Robert E.
    Knudsen, Lotte B.
    Simpson, Richard W.
    Dear, Anthony E.
    DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (01): : 79 - 79
  • [5] The GLP-1 Receptor Agonist Liraglutide Improves Hepatic Inflammation and Fibrosis in a Mouse Model of NASH
    Montandon, Sophie A.
    Somm, Emmanuel
    De Vito, Claudio
    Jornayvaz, Francois R.
    DIABETES, 2019, 68
  • [6] Liraglutide, GLP-1 receptor agonist, for chronic weight loss
    Moore, Katherine G.
    Shealy, Kayce
    Clements, Jennifer N.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (05) : 373 - 378
  • [7] EphA2 knockdown attenuates atherosclerotic lesion development in ApoE-/- mice
    Jiang, Hong
    Li, Xinyun
    Zhang, Xiaoli
    Liu, Yan
    Huang, Shanying
    Wang, Xiaowei
    CARDIOVASCULAR PATHOLOGY, 2014, 23 (03) : 169 - 174
  • [8] Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE-/- mice
    Zhang, Lizhi
    Li, Peicheng
    Tang, Zhaosheng
    Dou, Qin
    Feng, Bo
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (16)
  • [9] FDA approval of GLP-1 receptor agonist (liraglutide) for use in children
    Bacha, Fida
    LANCET CHILD & ADOLESCENT HEALTH, 2019, 3 (09): : 595 - 597
  • [10] Deficiency of the anticoagulant annexin A5 attenuates atherosclerotic plaque development in ApoE-/- mice
    Kusters, D.
    Chatrou, M. L. L.
    Willems, B. A. G.
    Schutters, K.
    Schurgers, L. J.
    Reutelingsperger, C. P. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 156 - 156
12345